Cargando…

(68)Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE)

SIMPLE SUMMARY: TARE with (90)Yttrium has become a valuable treatment option for patients with unresectable NELMs. However, early evaluation of therapy response remains challenging as size-based response assessments (such as RECIST) are known to be limited, especially in slow-growing tumors. Alterna...

Descripción completa

Detalles Bibliográficos
Autores principales: Ingenerf, Maria, Kiesl, Sophia, Karim, Salma, Beyer, Leonie, Ilhan, Harun, Rübenthaler, Johannes, Seidensticker, Max, Ricke, Jens, Schmid-Tannwald, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431353/
https://www.ncbi.nlm.nih.gov/pubmed/34503131
http://dx.doi.org/10.3390/cancers13174321
_version_ 1783750916824891392
author Ingenerf, Maria
Kiesl, Sophia
Karim, Salma
Beyer, Leonie
Ilhan, Harun
Rübenthaler, Johannes
Seidensticker, Max
Ricke, Jens
Schmid-Tannwald, Christine
author_facet Ingenerf, Maria
Kiesl, Sophia
Karim, Salma
Beyer, Leonie
Ilhan, Harun
Rübenthaler, Johannes
Seidensticker, Max
Ricke, Jens
Schmid-Tannwald, Christine
author_sort Ingenerf, Maria
collection PubMed
description SIMPLE SUMMARY: TARE with (90)Yttrium has become a valuable treatment option for patients with unresectable NELMs. However, early evaluation of therapy response remains challenging as size-based response assessments (such as RECIST) are known to be limited, especially in slow-growing tumors. Alternatives such as quantitative evaluation of SUV of (68)Ga-DOTATATE PET/CT and ADC of DWI-MRI have not been compared so far. We found that early percentage changes in SUV tumor-to-organ ratios on first follow-up after TARE could predict longer HPFS in patients with NELM and were superior to ΔSUVmax/SUVmean alone or to ΔADC. ABSTRACT: The aim of this study was to evaluate the role of SUV and ADC in assessing early response in patients with NELM following TARE. Thirty-two patients with pre- and postinterventional MRI with DWI and (68)Ga-DOTATATE PET/CT were included. ADC and SUV of three target lesions and of tumor-free spleen and liver tissue were determined on baseline and first follow-up imaging, and tumor to spleen (T/S) and tumor to liver (T/L) ratios were calculated. Response was assessed by RECIST 1.1 and mRECIST on first follow-up, and long-term response was defined as hepatic progression-free survival (HPFS) over 6, 12, and <24 months. In responders, intralesional ADC values increased and SUV decreased significantly regardless of standard of reference for response assessment (mRECIST/RECIST/HPFS > 6/12/24 m). Using ROC analysis, ΔSUV T/S ratio (max/max) and ΔSUV T/L ratio (max/mean) were found to be the best and most robust metrics to correlate with longer HPFS and were superior to ΔADC. ΔT/S ratio (max/max) < 23% was identified as an optimal cut-off to discriminate patients with longer HPFS (30.2 m vs. 13.4 m; p = 0.0002). In conclusion, early percentage changes in SUV tumor-to-organ ratios on first follow-up seem to represent a prognostic marker for longer HPFS and may help in assessing therapeutic strategies.
format Online
Article
Text
id pubmed-8431353
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84313532021-09-11 (68)Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE) Ingenerf, Maria Kiesl, Sophia Karim, Salma Beyer, Leonie Ilhan, Harun Rübenthaler, Johannes Seidensticker, Max Ricke, Jens Schmid-Tannwald, Christine Cancers (Basel) Article SIMPLE SUMMARY: TARE with (90)Yttrium has become a valuable treatment option for patients with unresectable NELMs. However, early evaluation of therapy response remains challenging as size-based response assessments (such as RECIST) are known to be limited, especially in slow-growing tumors. Alternatives such as quantitative evaluation of SUV of (68)Ga-DOTATATE PET/CT and ADC of DWI-MRI have not been compared so far. We found that early percentage changes in SUV tumor-to-organ ratios on first follow-up after TARE could predict longer HPFS in patients with NELM and were superior to ΔSUVmax/SUVmean alone or to ΔADC. ABSTRACT: The aim of this study was to evaluate the role of SUV and ADC in assessing early response in patients with NELM following TARE. Thirty-two patients with pre- and postinterventional MRI with DWI and (68)Ga-DOTATATE PET/CT were included. ADC and SUV of three target lesions and of tumor-free spleen and liver tissue were determined on baseline and first follow-up imaging, and tumor to spleen (T/S) and tumor to liver (T/L) ratios were calculated. Response was assessed by RECIST 1.1 and mRECIST on first follow-up, and long-term response was defined as hepatic progression-free survival (HPFS) over 6, 12, and <24 months. In responders, intralesional ADC values increased and SUV decreased significantly regardless of standard of reference for response assessment (mRECIST/RECIST/HPFS > 6/12/24 m). Using ROC analysis, ΔSUV T/S ratio (max/max) and ΔSUV T/L ratio (max/mean) were found to be the best and most robust metrics to correlate with longer HPFS and were superior to ΔADC. ΔT/S ratio (max/max) < 23% was identified as an optimal cut-off to discriminate patients with longer HPFS (30.2 m vs. 13.4 m; p = 0.0002). In conclusion, early percentage changes in SUV tumor-to-organ ratios on first follow-up seem to represent a prognostic marker for longer HPFS and may help in assessing therapeutic strategies. MDPI 2021-08-27 /pmc/articles/PMC8431353/ /pubmed/34503131 http://dx.doi.org/10.3390/cancers13174321 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ingenerf, Maria
Kiesl, Sophia
Karim, Salma
Beyer, Leonie
Ilhan, Harun
Rübenthaler, Johannes
Seidensticker, Max
Ricke, Jens
Schmid-Tannwald, Christine
(68)Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE)
title (68)Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE)
title_full (68)Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE)
title_fullStr (68)Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE)
title_full_unstemmed (68)Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE)
title_short (68)Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE)
title_sort (68)ga-dotatate pet/ct and mri with diffusion-weighted imaging (dwi) in short- and long-term assessment of tumor response of neuroendocrine liver metastases (nelm) following transarterial radioembolization (tare)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431353/
https://www.ncbi.nlm.nih.gov/pubmed/34503131
http://dx.doi.org/10.3390/cancers13174321
work_keys_str_mv AT ingenerfmaria 68gadotatatepetctandmriwithdiffusionweightedimagingdwiinshortandlongtermassessmentoftumorresponseofneuroendocrinelivermetastasesnelmfollowingtransarterialradioembolizationtare
AT kieslsophia 68gadotatatepetctandmriwithdiffusionweightedimagingdwiinshortandlongtermassessmentoftumorresponseofneuroendocrinelivermetastasesnelmfollowingtransarterialradioembolizationtare
AT karimsalma 68gadotatatepetctandmriwithdiffusionweightedimagingdwiinshortandlongtermassessmentoftumorresponseofneuroendocrinelivermetastasesnelmfollowingtransarterialradioembolizationtare
AT beyerleonie 68gadotatatepetctandmriwithdiffusionweightedimagingdwiinshortandlongtermassessmentoftumorresponseofneuroendocrinelivermetastasesnelmfollowingtransarterialradioembolizationtare
AT ilhanharun 68gadotatatepetctandmriwithdiffusionweightedimagingdwiinshortandlongtermassessmentoftumorresponseofneuroendocrinelivermetastasesnelmfollowingtransarterialradioembolizationtare
AT rubenthalerjohannes 68gadotatatepetctandmriwithdiffusionweightedimagingdwiinshortandlongtermassessmentoftumorresponseofneuroendocrinelivermetastasesnelmfollowingtransarterialradioembolizationtare
AT seidenstickermax 68gadotatatepetctandmriwithdiffusionweightedimagingdwiinshortandlongtermassessmentoftumorresponseofneuroendocrinelivermetastasesnelmfollowingtransarterialradioembolizationtare
AT rickejens 68gadotatatepetctandmriwithdiffusionweightedimagingdwiinshortandlongtermassessmentoftumorresponseofneuroendocrinelivermetastasesnelmfollowingtransarterialradioembolizationtare
AT schmidtannwaldchristine 68gadotatatepetctandmriwithdiffusionweightedimagingdwiinshortandlongtermassessmentoftumorresponseofneuroendocrinelivermetastasesnelmfollowingtransarterialradioembolizationtare